real world evidence rwe real world data rwd webinar programmers drug development Wisdom from the Front Lines of Successful NDA Submission Statistical Clinical Programming biostatistics cro mms holdings vendor services pharmaceutical industry biotech

MMS is proud to present our latest webinar – Wisdom from the Front Lines of Successful NDA Submission Programming: Utilizing the Biometrics Operational Data Model.

In this free, on-demand webinar you will discover:

  • The Biometrics Operational Data Model and explain how submission work can be streamlined across programmers and statisticians
  • Validation needs within a submission
  • The importance of reviewer’s guides and when they should be built
  • Why the NDA submission should be considered during early phases
  • Trial domains and how they relate to SDTM, ADaM, and TLFs
  • Items that are easy to overlooked during submission planning

Panelists include:

  • Jim Bademian, Global Head of Statistical Programming, MMS, North Carolina
  • Susheel Arkala, Principal Clinical Programmer and Associate Manager of Programming, MMS, Oregon
  • Chris Hurley, Senior Manager of Global Data Operations, Standards and Systems, MMS, Michigan

View the webinar here

Wisdom from the Front Lines of Successful NDA Submission Programming mms holdings webinar pharma cro biostatistics clinical statistical

Run time: 40:47

Suggested For You

perspectives

July 1st, 2025

Why Real-Time Data Access Matters (and How to Make the Most of It)

perspectives

June 24th, 2025

Why Now Is the Time for Specialized, Data-Focused CRO Partners

perspectives

June 17th, 2025

Solving Data Complexity with Real-Time Insights, Predictive AI, and Smarter Decision-Making with Datacise

perspectives

June 10th, 2025

Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives 

perspectives

June 3rd, 2025

Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions 

perspectives

May 28th, 2025

A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

perspectives

May 20th, 2025

Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn

perspectives

April 24th, 2025

How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products